Picoplatin pharmacokinetics and chemotherapy of non-small cell lung cancer

Bibliography

• Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7(8):573-84
   PubMed Web of Science ®Google Scholar
• d'Amato TA, Landreneau RJ, Ricketts W, et al. Chemotherapy resistance and oncogene expression in non-small cell lung cancer. J Thorac Cardiovasc Surg 2007;133:352-63
   PubMed Web of Science ®Google Scholar
• Kelland L. Broadening the clinical use of platinum drug-based chemotherapy with new analogues. satraplatin and picoplatin. Expert Opin Investig Drugs 2007;16(7):1009-21
   PubMed Web of Science ®Google Scholar
• Wheate NJ, Collins JG. Multinuclear platinum complexes as anticancer drugs. Coordination Chem Rev 2003;241(1-2):133-45
   Web of Science ®Google Scholar
• Olszewski U, Hamilton G. A better platinum-based anticancer drug yet to come? Anticancer Agents Med Chem 2010;10(4):293-301
   PubMed Web of Science ®Google Scholar
• Monneret C. Platinum anticancer drugs. From serendipity to rational design. Ann Pharm Fr 2011;69(6):286-95
   PubMedGoogle Scholar
• Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012;31(15):1869-83
   PubMed Web of Science ®Google Scholar
• Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22(47):7265-79
   PubMed Web of Science ®Google Scholar
• Rudin CM, Yang Z, Schumaker LM, et al. Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res 2003;63(2):312-18
   PubMed Web of Science ®Google Scholar
• Godwin AK, Meister A, O'Dwyer PJ, et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 1992;89(7):3070-4
   PubMed Web of Science ®Google Scholar
• Hay MP. ZD-0473 AstraZeneca. Curr Opin Investig Drugs 2000;1(2):263-6
   PubMedGoogle Scholar
• Battle AR, Choi R, Hibbs DE, Hambley TW. Platinum(IV) analogues of AMD473 (cis-[PtCl2(NH3)(2-picoline)]): preparative, structural, and electrochemical studies. Inorg Chem 2006;45(16):6317-22
   PubMed Web of Science ®Google Scholar
• Poniard Pharmaceuticals (online) accessed December 2012
   Google Scholar
• Kelland LR, Sharp SY, O'Neill CF, et al. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance. J Inorg Biochem 1999;77(1-2):111-15
   PubMed Web of Science ®Google Scholar
• Mistry P, Kelland L R, Abel G, et al. The relationships between glutathione, glutathione S. transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 1991;64:215-20
   PubMed Web of Science ®Google Scholar
• Raynaud FI, Boxall FE, Goddard PM, et al. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. Clin Cancer Res 1997;3(11):2063-74
   PubMed Web of Science ®Google Scholar
• Medina-Gundrum L, Cerna C, Gomez LR, et al. AMD473 (ZD0473) exhibits marked in vitro anticancer activity in human tumor specimens taken directly from patients. Anticancer Drugs 2003;14(4):275-80
   PubMed Web of Science ®Google Scholar
• Holford J, Raynaud F, Murrer BA, et al. Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum coordination complex, cis-[amminedichloro (2-methylpyridine)] platinum(II) (AMD473). Anticancer Drug Des 1998;13:1-18
   PubMedGoogle Scholar
• Holford J, Sharp SY, Murrer BA, et al. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer 1998;77:366-73
   PubMed Web of Science ®Google Scholar
• Sharp SY, O'Neill CF, Rogers P, et al. Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin. Eur J Cancer 2002;38:2309-15
   PubMed Web of Science ®Google Scholar
• Holford J, Beale PJ, Boxall FE, et al. Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines. Eur J Cancer 2000;36(15):1984-90
   PubMed Web of Science ®Google Scholar
• Raaphorst GP, Yang DP, Li LF, Malone S. Comparison of human tumour cell responses to cisplatin and ZD0473 with and without irradiation. Anticancer Res 2004;24(2B):613-18
   PubMed Web of Science ®Google Scholar
• Gore ME, Atkinson RJ, Thomas H, et al. A phase II trial of ZD0473 in platinum-pretreated ovarian cancer. Eur J Cancer 2002;38(58):2416-20
   PubMedGoogle Scholar
• Eckardt JR, Bentsion DL, Lipatov ON, et al. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. J Clin Oncol 2009;27:2046-51
   PubMed Web of Science ®Google Scholar
• Shah N, Dizon DS. New-generation platinum agents for solid tumors. Future Oncol 2009;5:33-42
   PubMed Web of Science ®Google Scholar
• Kanzawa F, Akiyama Y, Saijo N, Nishio K. In vitro effects of cis-amminedichloro (2-methylpyridine) platinum (II) (ZD0473) with other novel anticancer drugs on the growth of SBC-3, a human small cell lung cancer line. Lung Cancer 2003;40:325-32
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Vandenberg TA, Panasci L, et al. A phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group trial, IND 129. Ann Oncol 2003;14(4):543-8
   PubMed Web of Science ®Google Scholar
• Solomon B, Bunn PA Jr. Adjuvant chemotherapy for non-small cell lung cancer. Cancer Invest 2007;25(4):217-25
   PubMed Web of Science ®Google Scholar
• Bunn PA Jr. Platinums in lung cancer: sufficient or necessary? J Clin Oncol 2005;23:2882-3
   PubMed Web of Science ®Google Scholar
• D'Addario G, Früh M, Reck M, et al. ESMO Guidelines Working Group. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(S5):116-19
   Google Scholar
• d'Amato TA, Landreneau RJ, Ricketts W, et al. Chemotherapy resistance and oncogene expression in non-small cell lung cancer J Thorac Cardiovasc Surg 2007;133(2):352-63
   PubMed Web of Science ®Google Scholar
• Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer-is it becoming a reality? Nat Rev Clin Oncol 2010;7(7):401-14
   PubMed Web of Science ®Google Scholar
• O’Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small- cell lung cancer. J Clin Oncol 2006;24:5441-7
   PubMed Web of Science ®Google Scholar
• Tang CH, Parham C, Shocron E, et al. Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin. Cancer Chemother Pharmacol 2011;67(6):1389-400
   PubMed Web of Science ®Google Scholar
• Kawamura-Akiyama Y, Kusaba H, Kanzawa F, et al. Non-cross resistance of ZD0473 in acquired cisplatin-resistant lung cancer cell lines. Lung Cancer 2002;38:43-50
   PubMed Web of Science ®Google Scholar
• Treat J, Schiller J, Quoix E, et al. ZD0473 treatment in lung cancer: an overview of the clinical trial results. Eur J Cancer 2002;38(S8):S13-18
   PubMedGoogle Scholar
• William WN Jr, Glisson BS. Novel strategies for the treatment of small-cell lung carcinoma. Nat Rev Clin Oncol 2011;8(10):611-19
   PubMed Web of Science ®Google Scholar
• Ciuleanu T, Samarzjia M, Demidchik Y, et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy. J Clin Oncol 2010;28(15S):abstract 7002
   Google Scholar
• Beale P, Judson I, O'Donnell A, et al. A phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473). Br J Cancer 2003;88(7):1128-34
   PubMed Web of Science ®Google Scholar
• Murakami H, Tamura T, Yamada Y, et al. ZD0473 pharmacokinetics in Japanese patients: a phase I dose-escalation study. Eur J Cancer 2002;38(S8):S1-5
   PubMedGoogle Scholar
• Stevenson JP, Blair IA, Redlinger M, et al. Pharmacokinetikg (Pk)/pharmacodynamik (PD) trial of the new generation platinum compound ZD0473 administered as an i.v. infusion every 21 days [Poster 255]. Proc ASCO; 2001
   Google Scholar
• Delord JP, Puozzo C, Lefresne F, Bugat R. Combination chemotherapy of vinorelbine and cisplatin: a phase I pharmacokinetic study in patients with metastatic solid tumors. Anticancer Res 2009;29(2):553-60
   PubMed Web of Science ®Google Scholar
• Yee L, Sharma S, Breitz H, et al. A Phase I Randomized Crossover Oral Picoplatin Bioavailability Pharmacokinetics and Pharmacodynamics Study [Poster Number 209]. AACR, Clinical Research Session; 2008
   Google Scholar
• Gelmon KA, Stewart D, Chi KN, et al. A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131. Ann Oncol 2004;15(7):1115-22
   PubMed Web of Science ®Google Scholar
• Twelves C, Reck M, Anthoney A, et al. A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies. Cancer Chemother Pharmacol 2003;52(4):277-81
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Stevenson JP, Redlinger M, et al. A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine. Cancer Chemother Pharmacol 2004;53(5):404-8
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009;27(32):5431-8
   PubMed Web of Science ®Google Scholar
• Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007;33(1):9-23
   PubMed Web of Science ®Google Scholar
• Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev 2012;64(3):706-21
   PubMed Web of Science ®Google Scholar
• Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007;63(1):12-31
   PubMed Web of Science ®Google Scholar
• Kasherman Y, Sturup S, Gibson D. Is glutathione the major cellular target of cisplatin? a study of the interactions of cisplatin with cancer cell extracts. J Med Chem 2009;52(14):4319-28
   PubMed Web of Science ®Google Scholar
• Byun SS, Kim SW, Choi H, et al. Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities. BJU Int 2005;95(7):1086-90
   PubMed Web of Science ®Google Scholar
• Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. Oncol Rep 2003;10(6):1663-82
   PubMed Web of Science ®Google Scholar
• Brown SD, Trotter KD, Sutcliffe OB, et al. Combining aspects of the platinum anticancer drugs picoplatin and BBR3464 to synthesize a new family of sterically hindered dinuclear complexes; their synthesis, binding kinetics and cytotoxicity. Dalton Trans 2012;41(37):11330-9
   PubMed Web of Science ®Google Scholar
• Wheate NJ, Walker S, Craig GE, Oun R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans 2010;39(35):8113-27
   PubMed Web of Science ®Google Scholar
• Ravera M, Gabano E, Zanellato I, et al. Synthesis, characterization and antiproliferative activity on mesothelioma cell lines of bis(carboxylato)platinum(IV) complexes based on picoplatin. Dalton Trans 2012;41(11):3313-20
   PubMed Web of Science ®Google Scholar
• Pazout R, Maixner J, Hrdá M, et al. A bromine analogue of picoplatin: a new substance from the group of platinum-based chemotherapeutics. Acta Cristallogr C 2013;69(4):337-9
   PubMed Web of Science ®Google Scholar
• Olszewski U, Ach F, Ulsperger E, et al. In vitro evaluation of oxoplatin: an oral platinum(IV) anticancer agent. Met Based Drugs 2009;2009:348916
   PubMedGoogle Scholar